Cannabis Suisse Corp (CSUI) Q3 2025 Earnings Report

Previous: Q2 2025

Cannabis Suisse Corp

CSUI

$0.00530 0.00%

Exchange: OTC | Sector: Healthcare | Industry: Drug Manufacturers Specialty Generic

Q3 2025

Published: Apr 17, 2025

Earnings Highlights

Revenue of $0.01M up 0% year-over-year
EPS of $0.00 increased by 126.7% from previous year
Gross margin of 1.9%
Net income of 29.52K
"" -

CSUI

Company CSUI

Period Q3 2025

Currency USD

Report Type Quarterly Earnings

Generated Dec 8, 2025

Executive Summary

Cannabis Suisse Corp (CSUI) delivered QQ3 2025 results that depict a flat revenue trajectory but a materially distressed liquidity position. Reported revenue of 7,500 USD with a gross profit of 144 USD yields a thin gross margin of 1.92%. Operating activities generated a negative cash flow of 11,450 USD, and free cash flow was also negative by 11,450 USD, while cash at period-end stood at 50 USD. The company carries a substantial debt burden (total debt 2,464,884 USD; long-term debt 2,226,267 USD) and a balance sheet with total assets of 691,107 USD against liabilities of 2,537,446 USD, producing negative stockholders’ equity (-1,846,339 USD). The result is a weak liquidity profile (current ratio 0.379) and an almost non-existent cash cushion, indicating an acute refinancing and solvency risk unless a material capital event or strategic restructuring occurs.

Key Performance Indicators

Revenue

Stable

7.50K

QoQ: 0.00% | YoY: 0.00%

Gross Profit

Increasing

144.00

1.92% margin

QoQ: 0.00% | YoY: 132.95%

Operating Income

Decreasing

-65.73K

QoQ: 27.97% | YoY: -4.56%

Net Income

Increasing

29.52K

QoQ: 483.07% | YoY: 143.42%

EPS

Increasing

0.00

QoQ: 300.00% | YoY: 126.67%

Revenue Trend

Margin Analysis

Financial Highlights

Revenue: 7,500 USD; YoY 0.00%, QoQ 0.00%. Gross Profit: 144 USD; Gross Margin 1.92%; YoY 132.95%, QoQ 0.00%. Operating Income: -65,727 USD; Operating Margin -8.76%; YoY -4.56%, QoQ +27.97%. EBITDA: -65,727 USD; EBITDA Margin -8.76%. Net Income: 29,515 USD; Net Margin 3.94%; YoY +143.42%, QoQ +483.07%. EPS: 0.0004; Diluted 0.0001; YoY +126.67%, QoQ +300.00%. Cash flow from operations: -11,450 USD; Free cash flow: -11,450 USD. Cash at end of period: 50 USD; Cash at beginning: 4,100 USD. Balance sheet highlights: Total assets 691,107 USD; Total liabilities 2,537,446 USD; Total stockholders’ equity -1,846,339 USD. Debt metrics: Total debt 2,464,884 USD; Net debt 2,464,884 USD. Liquidity ratios: Current ratio 0.379; Quick ratio 0.379; Cash ratio 0.000161.

Income Statement

Metric	Value	YoY Change	QoQ Change
Revenue	7.50K	0.00%	0.00%
Gross Profit	144.00	132.95%	0.00%
Operating Income	-65.73K	-4.56%	27.97%
Net Income	29.52K	143.42%	483.07%
EPS	0.00	126.67%	300.00%

Key Financial Ratios

Gross Profit Margin

Weak

1.92%

Gross profit margin is below industry norms, profitability concerns

Operating Profit Margin

Weak

-8.76%

Operating margin is below industry norms, profitability concerns

Net Profit Margin

Fair

3.94%

Net profit margin is moderate, room for improvement in cost management

Return on Assets

Fair

4.27%

Return on assets is acceptable but below top-tier companies

Return on Equity

Weak

-0.02%

Return on equity suggests inefficient capital allocation

Current Ratio

Concern

0.38

Current ratio below safe levels, potential liquidity risk

Debt to Equity

Conservative

-1.34

Debt-to-equity shows conservative leverage and low financial risk

P/E Ratio

Value

10.18x

P/E ratio suggests potential undervaluation or stable earnings

Price to Book

Undervalued

-0.65x

Trading below book value, potential value opportunity or distressed

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q3 2025	0.01	0.00	+0.0%	View
Q2 2025	0.01	0.00	+0.0%	View
Q1 2025	0.01	-0.01	+0.0%	View
Q4 2024	0.01	-0.02	+0.0%	View
Q3 2024	0.01	0.00	+200.0%	View

CSUI

Cannabis Suisse Corp

Q2 2025 Report

Cannabis Suisse Corp (CSUI) QQ2 2025 Results Analysis – Healthcare | Drug Manufacturers (Specialty & Generic) with a Distressed Balance Sheet...

Read full report

CSUI

Cannabis Suisse Corp

Q1 2025 Report

Cannabis Suisse Corp (CSUI) QQ1 2025 Results: Flat Revenue, Deep Losses and Elevated Leverage...

Read full report

CSUI

Cannabis Suisse Corp

Q4 2024 Report

Cannabis Suisse Corp (CSUI) QQ4 2024 Financial Results Analysis – Healthcare: Drug Manufacturers (Specialty / Generic) – Severe Losses, Leverage B...

Read full report

CSUI

Cannabis Suisse Corp

Q3 2024 Report

Cannabis Suisse Corp (CSUI) QQ3 2024 Results Analysis — Revenue $7.5k, Escalating Losses, and Acute Balance Sheet Strain...

Read full report

Cannabis Suisse Corp (CSUI) Q3 2025 Earnings Report

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Financial Highlights

Income Statement

Key Financial Ratios

Management Insights Available for Members

Peer Comparison Available for Members

Investment Outlook & SWOT Available for Members

Historical Earnings Comparison

More CSUI Quarterly Reports

CSUI

CSUI

CSUI

CSUI

Q3 2025 Reports in Healthcare Sector

Related Financial Data

Sector Analysis: Healthcare

CSUI Full Profile

CSUI Financial Statements

Earnings Calendar